ORCID Profile
0000-0002-4660-5297
Current Organisation
Monash University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Medknow
Date: 05-02-2017
Publisher: Wiley
Date: 05-10-2021
Abstract: Assembled protein particles, as emerging biomaterials, have broad applications ranging from vaccines and drug delivery to biocatalysis and particle tracking, but to date these require trial‐and‐error rational design experimentation and/or intensive computational methods to generate. Here, the authors describe an easy‐to‐implement engineering strategy to generate customized protein particles as multifunctional biomaterials. They utilize protein–peptide modules to generate functional nanoparticles whose assembly and size is controlled by the addition of mild stimuli. The protein assembling method is versatile, as exemplified through particle formation with 7 distinct protein modules, using a variety of assembly conditions tailored by the chemistries of 3 peptide partners. They have generated customized protein particles using enzymes, binding and reporter proteins, and their functions and utilities are demonstrated using biocatalysis, sensing, and labelling applications, respectively. Furthermore, co‐assembly with two functional proteins within one particle has been successfully achieved and demonstrated. Physical insights into the kinetics and molecular mechanisms of particle formation are revealed by small angle X‐ray scattering and mass photometry, providing fundamental knowledge to guide design and manufacture these interesting biomaterials in future. Their protein assembling strategy is a reliable method for fabricating a protein particle to deliver new functionalities on‐demand.
Publisher: American Chemical Society (ACS)
Date: 18-09-2020
Publisher: American Chemical Society (ACS)
Date: 04-10-2022
Abstract: Antibiotic resistance represents a serious global health concern and has stimulated the development of antimicrobial nanomaterials to combat resistant bacteria. Protein-based nanoparticles combining characteristics of both proteins and nanoparticles offer advantages including high biocompatibility, attractive biodegradability, enhanced bioavailability and functional versatility. They have played an increasing role as promising candidates for broad applications ranging from biocatalysts and drug delivery to vaccine development to cancer therapeutics. However, their application as antibacterial biomaterials to address challenging antibiotic-resistance problems has not been explicitly pursued. Herein, we describe engineering protein-only nanoparticles against resistant Gram-positive bacteria. A self-assembling peptide (P
Publisher: Elsevier BV
Date: 03-2021
Publisher: Wiley
Date: 15-01-2023
Abstract: RNA molecules have emerged as increasingly attractive biomaterials with important applications such as RNA interference (RNAi) for cancer treatment and mRNA vaccines against infectious diseases. However, it remains challenging to engineer RNA biomaterials with sophisticated functions such as non‐covalent light‐switching ability. Herein, light‐responsive RNA‐protein nanowires are engineered to have such functions. It first demonstrates that the high affinity of RNA aptamer enables the formation of long RNA‐protein nanowires through designing a dimeric RNA aptamer and an engineered green fluorescence protein (GFP) that contains two TAT‐derived peptides at N‐ and C‐ termini. GFP is then replaced with an optogenetic protein pair system, LOV2 (light–oxygen–voltage) protein and its binding partner ZDK (Z subunit of protein A), to confer blue light‐controlled photo‐switching ability. The light‐responsive nanowires are long ( nm) in the dark, but small (20–30 nm) when exposed to light. Importantly, the co‐assembly of this RNA‐protein hybrid biomaterial does not rely on the photochemistry commonly used for light‐responsive biomaterials, such as bond formation, cleavage, and isomerization, and is thus reversible. These RNA‐protein structures can serve as a new class of light‐controlled biocompatible frameworks for incorporating versatile elements such as RNA, DNA, and enzymes.
Publisher: Wiley
Date: 05-12-2022
Abstract: RNA aptamers bind specifically and selectively to various macromolecules, cell surfaces, and viruses and find broad applications as biosensors, diagnostics, and in therapeutic treatments and drug delivery. Currently, RNA aptamer production is via in vitro methods. Herein, a new E. coli ‐based approach has been demonstrated for the rapid production of multimeric RNA aptamer transcripts that are protected from degradation by burying the 5′ and 3′ ends of the transcript in a designed double‐stranded spacer. Multimeric and fluorescent RNA aptamers were produced stably in vivo and readily isolated from RNase III‐deficient cells, and their full functionalities were shown by binding assays and fluorescence measurements. This approach shows promise as a rapid and scalable bioprocess for the production of RNA aptamers at low cost.
Publisher: International Journal of Biosciences
Date: 30-09-2018
Publisher: Informa UK Limited
Date: 03-2019
DOI: 10.2147/IDR.S189884
Publisher: Medknow
Date: 05-02-2017
Publisher: Informa UK Limited
Date: 10-08-2021
Publisher: MedCrave Group, LLC
Date: 30-10-2017
Publisher: Pakistan Journal of Agricultural Sciences
Date: 09-2016
No related grants have been discovered for Tayyaba Younas.